共 50 条
- [41] COST-EFFECTIVENESS ANALYSIS OF NOVEL THERAPIES FOR HER2+METASTATIC BREAST CANCER: [FAM-] TRASTUZUMAB DERUXTECAN VERSUS TUCATINIB TRASTUZUMAB AND CAPECITABINE COMBINATIONVALUE IN HEALTH, 2020, 23 : S433 - S434Vondeling, G.Palaka, E.Livings, C.Naik, J.Sullivan, W.
- [42] MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (trial in progress)ANNALS OF ONCOLOGY, 2022, 33 (07) : S734 - S735Andre, T.Bekaii-Saab, T.Tabernero, J.Siena, S.Yoshino, T.Norwood, K. G.Adelberg, D. E.Ward, J.Yang, S.Strickler, J. H.Van Cutsem, E.
- [43] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerNEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734Swain, Sandra M.Baselga, JoseKim, Sung-BaeRo, JungsilSemiglazov, VladimirCampone, MarioCiruelos, EvaFerrero, Jean-MarcSchneeweiss, AndreasHeeson, SarahClark, EmmaRoss, GrahamBenyunes, Mark C.Cortes, Javier
- [44] Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)CANCER RESEARCH, 2022, 82 (04)Lin, Nancy U.Murthy, Rashmi K.Abramson, VandanaAnders, CareyBachelot, ThomasBedard, PhilippeBorges, VirginiaCameron, DavidCameron, DavidCarey, LisaChien, A. JoCurigliano, GiuseppeDiGiovanna, MichaelGelmon, KarenHortobagyi, GabrielHurvitz, SaraKrop, IanLoi, ShereneLoibl, SibylleMueller, VolkmarOliveira, MafaldaPaplomata, ElisavetPegram, MarkSlamon, DennisZelnak, AmeliaRamos, JorgeFeng, WentaoWiner, Eric
- [45] Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+metastatic breast cancer (MBC) who failed prior trastuzumab therapyANNALS OF ONCOLOGY, 2017, 28 : 30 - 30Lee, S. C.Chen, S-C.Dai, M-S.Lee, G. E.Liu, C-L.Chan, A.Chang, H-K.Tseng, L-M.Chay, W. Y.Chow, L. W. C.Peneyra, J. L.Rau, K-M.Wang, H-C.Guancia, A. A.Head, M.Chiu, J. W. Y.Robinson, B.Lindmark, B.McIntyre, N.Hsieh, C-Y.
- [46] MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS261 - TPS261Bekaii-Saab, Tanios S.Van Cutsem, EricTabernero, JosepSiena, SalvatoreYoshino, TakayukiNakamura, YoshiakiRaghav, Kanwal Pratap SinghCercek, AndreaHeinemann, VolkerAdelberg, David E.Ward, James EdwardYang, ShanAndre, ThierryStrickler, John H.
- [47] The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Andrieu, CharlotteAl-Sultan, DalalIvers, LauraPina, Jose Javier BerenguerSkrobo, DarkoBallot, JosephineEustace, Alex J.Gullo, GiuseppeCrown, John
- [48] Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab plus trastuzumab in HER2+metastatic breast cancer patients previously treated with trastuzumabCANCER RESEARCH, 2009, 69 (02) : 243S - 244SBaselga, J.Imadalou, K.Paton, VGray, D.Swain, S.
- [49] A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancerCLINICAL BREAST CANCER, 2006, 6 (06) : 535 - 539Walshe, Janice M.Denduluri, NeelimaBerman, Arlene W.Rosing, Douglas R.Swain, Sandra M.
- [50] HER2CLIMB-04: Phase II trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+unresectable locally-advanced or metastatic breast cancer with and without brain metastasesANNALS OF ONCOLOGY, 2021, 32 : S76 - S76Hamilton, E.Ramos, J.Feng, W.Krop, I.